Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2
作者:Senko Tsukuda、Tomoe Kusayanagi、Eri Umeda、Chihiro Watanabe、Yu-ta Tosaki、Shinji Kamisuki、Toshifumi Takeuchi、Yoichi Takakusagi、Isamu Shiina、Fumio Sugawara
DOI:10.1016/j.bmc.2012.10.037
日期:2013.1
Ridaifen B (RID-B) is a tamoxifen derivative that potently inhibits breast tumor growth. RID-B was reported to show anti-proliferating activity for a variety of estrogen receptor (ER)-positive human cancer cells. Interestingly, RID-B was also reported to possess higher potency than that of tamoxifen even for some ER-negative cells, suggesting an ER-independent mechanism of action. In this study, a T7 phage display screen and subsequent binding analyses have identified Grb10 interacting GYF protein 2 (GIGYF2) as a RID-B-binding protein. Using a cell-based assay, the Akt phosphorylation level mediated by GIGYF2 was found to have decreased in the presence of RID-B. (C) 2012 Elsevier Ltd. All rights reserved.